Enables single-stranded DNA binding activity. Predicted to be involved in several processes, including DNA metabolic process; regulation of cell cycle phase transition; and regulation of double-strand break repair via homologous recombination. Part of DNA replication factor A complex. Orthologous to human RPA2 (replication protein A2); PARTICIPATES IN mismatch repair pathway; nucleotide excision repair pathway; DNA replication pathway; INTERACTS WITH (+)-schisandrin B; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of RPA2 mRNA and Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to RPA2 promoter]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of RPA2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of RPA2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of RPA2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of RPA2 mRNA
[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of RPA2 mRNA and PPARA protein promotes the reaction [pirinixic acid results in increased expression of RPA2 mRNA]
quizartinib affects the reaction [RGFP966 results in increased phosphorylation of RPA2 protein] and RGFP966 affects the reaction [quizartinib results in increased phosphorylation of RPA2 protein]
quizartinib affects the reaction [RGFP966 results in increased phosphorylation of RPA2 protein] and RGFP966 affects the reaction [quizartinib results in increased phosphorylation of RPA2 protein]
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of RPA2 protein
A sequence in the N-terminal region of human uracil-DNA glycosylase with homology to XPA interacts with the C-terminal part of the 34-kDa subunit of replication protein A.
Replication protein A is the major single-stranded DNA binding protein detected in mammalian cell extracts by gel retardation assays and UV cross-linking of long and short single-stranded DNA molecules.